Serological Test for SARS-CoV-2



Clinical assay for detecting SARS-CoV-2 neutralizing antibodies.

Key Benefits

  • Highly specific and sensitive.
  • Fewer false positives than commercially available tests.

Market Summary

SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing potency of the immune response during acute infection. COVID-19 serological tests are used to assess immunity and predict patient outcomes; however, many of the existing tests suffer from high error.

Technical Summary

The SARS-CoV-2 receptor binding domain (RBD) interacts with the ACE2 receptor to infect cells. RBD-specific IgG antibody responses are rapidly induced during severe and moderate acute COVID-19 infection, with most patients showing RBD-specific antibody responses by 6 days post-PCR confirmation. Researchers have developed and validated a sensitive and selective RBD-based clinical assay that correlates with viral neutralization.

Developmental Stage

Validated with retrospective clinical samples.


Patent Information

App Type Country Serial No. Patent No. File Date Issued Date Patent Status
Nationalized PCT - United States United States 17/922,670   11/1/2022   Pending
Tech ID: 20171
Published: 1/24/2022